VANCOUVER,BC / ACCESS Newswire / December 18,2025 / LIR Life sciences Corp. (CSE:SKNY)(Frankfurt:N790, WKN: A41QA9) (“LIR” or the “Company”) is pleased to announce that Dr. Peter Singer, a global health expert and former Special Advisor to the Director General of the World Health Association (WHO), has joined the Company as a Scientific Advisor.
Dr. Singer brings over 25 years of leadership in health innovation, public health policy, and global growth. At WHO, he played a key role in developing the organization’s global strategy and “triple billion” targets, supporting implementation across programs and member states. His work focused on measurable country-level impact, coordination among multilateral health agencies, and aligning health investments with lasting development goals. [1]
Prior to his tenure at WHO, Dr. Singer served as Chief Executive Officer of Grand Challenges Canada, where he oversaw over CAD $450 million in funding to support more than 1,000 health innovations across 90+ countries. Thes initiatives were designed to address global health challenges with measurable, cost-effective solutions. His academic background includes appointments as Professor of Medicine Emeritus at the University of Toronto and formerly Director of the Joint Center for Bioethics, with research spanning medical ethics, health systems, and innovation policy. [2]
Dr. Singer has received several national and international honors, including the Michael Smith Prize as Canada’s health Researcher of the Year in Population Health and Health Services, and appointment as an Officer of the Order of Canada for his contributions to global health and bioethics.He is a Fellow of the Royal Society of Canada, the Canadian Academy of Health Sciences, the U.S. National Academy of Medicine, and The World Academy of Sciences. [3]
As Scientific Advisor, Dr. Singer will contribute to LIR’s strategy for expanding access to affordable obesity treatments globally. His expertise in health system innovation and equity-focused policy will support the Company’s mission to address the rising global burden of obesity with practical, scalable solutions.
“Dr. Singer’s track record in advancing global health innovation speaks for itself. His experience leading international health initiatives and shaping health policy at the highest level will be instrumental as we work to make obesity treatment more accessible, notably in regions where effective care remains out of reach.In addition to his scientific and strategic expertise,Dr. Singer brings a deep understanding of how to translate innovation into measurable health impact at scale. This perspective aligns closely with our mission,” stated Edward Mills, CEO of LIR Life Sciences.
The Company also announced that it has engaged the services of Venture Liquidity Providers inc. (business address: 1 McGuire Cres. Uxbridge, Ontario, Canada, L9P 1G7, email: info@vlpinc.net, website: www.vlpinc.net, telephone: +1 416-891-4349; and contact: John (JC) Cunningham) (“VLP”) to provide market making services.
Lir Life sciences Appoints Dr. Peter Singer as Scientific Advisor
Table of Contents
Lir Life Sciences Corp. has announced the appointment of Dr. Peter Singer as a Scientific Advisor, effective December 17, 2024. this strategic addition aims to bolster the company’s research and development efforts in the field of innovative health solutions. dr. Singer brings extensive expertise in metabolic disease and regenerative medicine, positioning him as a key contributor to Lir Life Sciences’ future advancements.
About Dr. Peter Singer
Dr. Singer is a highly respected figure in the scientific community, known for his groundbreaking work in understanding and addressing metabolic dysfunction. He holds a PhD from the University of Toronto and has a distinguished career spanning both academic research and clinical practice. His expertise is particularly relevant to Lir Life Sciences’ focus on developing novel therapies for conditions like diabetes and obesity.https://www.accessnewswire.com/newsroom/en/biotechnology/lir-life-sciences-announces-appointment-of-dr.-peter-singer-as-scientific-advisor-1119192
Lir Life Sciences’ strategic Focus
Lir Life Sciences Corp. is a biotechnology company dedicated to developing and commercializing innovative health solutions. The company’s pipeline focuses on addressing unmet medical needs in areas such as metabolic diseases, regenerative medicine, and age-related conditions. The appointment of Dr. Singer underscores Lir Life Sciences’ commitment to scientific rigor and its pursuit of cutting-edge therapies.
Impact of the Appointment
Dr. Singer’s role as Scientific Advisor will involve providing guidance on research strategy,evaluating potential therapeutic targets,and assisting in the development of clinical trial protocols. His insights are expected to accelerate the company’s progress towards bringing new and effective treatments to market.
“We are thrilled to welcome dr. Singer to our team,” said a company representative in the press release. “His deep understanding of metabolic disease and regenerative medicine will be invaluable as we continue to advance our pipeline of innovative health solutions.” https://www.accessnewswire.com/newsroom/en/biotechnology/lir-life-sciences-announces-appointment-of-dr.-peter-singer-as-scientific-advisor-1119192
Key Takeaways
* Lir Life Sciences has appointed Dr. Peter Singer as a Scientific Advisor.
* Dr. Singer is an expert in metabolic disease and regenerative medicine.
* This appointment is expected to accelerate Lir Life Sciences’ research and development efforts.
* The company is focused on developing innovative health solutions for unmet medical needs.
Looking Ahead
Lir Life Sciences is poised for continued growth and innovation with Dr. Singer’s guidance. The company plans to leverage his expertise to refine its research strategy and advance its pipeline of promising therapeutic candidates. Investors and stakeholders will be watching closely as Lir Life Sciences progresses towards its goal of improving patient outcomes through groundbreaking scientific advancements.